| Literature DB >> 32984748 |
Yoshihiro Araki1, Norio Yamamoto1, Katsuhiro Hayashi1, Akihiko Takeuchi1, Shinji Miwa1, Kentaro Igarashi1, Yuta Taniguchi1, Hirotaka Yonezawa1, Sei Morinaga1, Hiroyuki Tsuchiya1.
Abstract
Giant-cell tumor of bone (GCTB) is a locally aggressive intermediate bone tumor with a rarely metastasizing disposition. Standard surgical treatment consists of curettage, adjuvant treatment, and augmentation with allograft, autograft, or synthetics. Polymethylmethacrylate (PMMA) has been widely used for augmentation of the bone defect; however, the hyperthermic polymerization of PMMA may cause damage to articular cartilage, and the stiffness of the material may decrease the ability of the joint to absorb shock. These properties were reported to result in secondary osteoarthritis. Calcium phosphate cement has a low degree of thermal reaction and a strength that is similar to cortical bone. The aim of the present study was to investigate the incidence of secondary osteoarthritis around the knee joint following augmentation with calcium phosphate cement.Entities:
Year: 2020 PMID: 32984748 PMCID: PMC7480969 DOI: 10.2106/JBJS.OA.19.00068
Source DB: PubMed Journal: JB JS Open Access ISSN: 2472-7245
Fig. 1Figs. 1-A through 1-F Preoperative CT and anteroposterior radiographs showing change in the knee joint of a 31-year-old woman with GCTB at the proximal aspect of the left tibia (Case 12, Table I). Fig. 1-A Coronal plane of the lesion with partial subchondral bone loss. Fig. 1-B Sagittal plane of the lesion with partial subchondral bone loss. Fig. 1-C Preoperative state. Fig. 1-D State at 3 months postoperatively. Fig. 1-E State at about 12 years postoperatively. Fig. 1-F State of the nonoperative contralateral knee at about 12 years postoperatively.
Fig. 2Kaplan-Meier curve for overall cartilage survival (Fig. 2-A) and cartilage survival with KL grade <3 (Fig. 2-B).
Fig. 3Figs. 3-A through 3-F Preoperative CT and anteroposterior radiographs showing change in the knee joint of a 59-year-old woman with GCTB at the distal aspect of the right femur (Case 10, Table I). Fig. 3-A Coronal plane of the lesion. Fig. 3-B Sagittal plane of the lesion. Fig. 3-C Preoperative state. Fig. 3-D Immediate postoperative state. Fig. 3-E State at about 6 years postoperatively. Fig. 3-F State of the nonoperative contralateral knee at about 6 years postoperatively.
Fig. 4Kaplan-Meier curve for disease-free survival.
Patient Characteristics*
| Case No. | Age in Years, Sex | Location | Size | Pathological Fracture | ASB | Dimensions of Exposed Articular Cartilage | Preop. KL Grade | KL Grade at Latest Follow-up | Contralateral KL Grade | Postop. Osteoarthritis | Bone-Modifying Agents | Follow-up Period | Additional Operation |
| 1 | 29, M | DF | 45 | No | 7% | 2 × 7 | 0 | 0 | 0 | – | – | 98 | Re-curettage |
| 2 | 30, M | DF | 36 | No | 3% | 3 × 6 | 0 | 3 | 0 | Secondary | – | 111 | OWHTO |
| 3 | 20, F | DF | 75 | Yes | 38% | 3 × 3 | 0 | 1 | 0 | Secondary | – | 102 | Hardware removal |
| 4 | 41, F | DF | 40 | No | 10% | 5 × 4 | 1 | 1 | 1 | – | – | 112 | – |
| 5 | 60, F | PT | 84 | No | 11% | 11 × 6 | 2 | 4 | 2 | Secondary | Denosumab | 112 | TKA |
| 6 | 33, F | PT | 90 | No | 27% | 2 × 4 | 1 | 1 | 1 | – | – | 117 | – |
| 7 | 35, F | DF | 66 | No | 17% | NA | 1 | 2 | 1 | Secondary | – | 128 | – |
| 8 | 43, M | PT | 39 | No | 10% | 0 | 1 | 1 | 1 | – | – | 139 | – |
| 9 | 28, M | DF | 57 | No | 17% | 5 × 6 | 0 | 0 | 0 | – | – | 66 | – |
| 10 | 59, F | DF | 96 | No | 21% | 8 × 9 | 1 | 3 | 1 | Secondary | Bisphosphonate | 69 | – |
| 11 | 27, M | DF | 66 | No | 8% | 0 | 0 | 0 | 0 | – | – | 140 | – |
| 12 | 31, F | PT | 66 | No | 42% | 5 × 6 | 0 | 0 | 0 | – | – | 141 | – |
| 13 | 63, F | PT | 15 | No | 13% | NA | 1 | 2 | 2 | Age-related | Bisphosphonate | 155 | – |
| 14 | 58, M | DF | 80 | No | 12% | NA | 1 | 1 | 1 | – | – | 165 | – |
| 15 | 26, F | PT | 42 | No | 18% | 0 | 0 | 0 | 0 | – | – | 172 | – |
| 16 | 33, F | DF | 32 | No | 10% | NA | 0 | 0 | 0 | – | – | 169 | – |
| 17 | 61, F | DF | 60 | No | 17% | NA | 1 | 2 | 2 | Age-related | – | 193 | – |
| 18 | 28, F | DF | 54 | No | 53% | 7 ×9 | 0 | 0 | 0 | – | – | 205 | – |
| 19 | 20, M | PT | 36 | No | 19% | 9 × 9 | 0 | 0 | 0 | – | Denosumab | 104 | – |
ASB = amount of subchondral bone involvement, preop. = preoperative, postop. = postoperative, DF = distal aspect of the femur, OWHTO = open-wedge high tibial osteotomy, PT = proximal aspect of the tibia, TKA = total knee arthroplasty, and NA = not applicable.
Previous Studies on the Incidence of Secondary Osteoarthritis and Recurrence Rate Following Curettage for GCTB*
| Author, Year | Cases | Average Follow-up | Bone Graft | Osteoarthritis Progression | Osteoarthritis Progression to KL 3-4 | Recurrence Rate |
| Suzuki,[ | 30 | 57 | PMMA | 10 (33%) | NA | 10 (33%) |
| Xu[ | 76 | 35 | PMMA | 23 (30%) | NA | 3 (6%) |
| van der Heijden[ | 53 | 86 | PMMA | NA | 8 (17%) | 15 (28%) |
| Caubère[ | 19 | 120 | PMMA | NA | 5 (26%) | 8 (42%) |
| Present study | 19 | 131 | CPC | 5 (26%) | 3 (16%) | 2 (11%) |
NA = not applicable